[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pathological-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pathological-response":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100644388","objective-sleep-characteristics-and-neoadjuvant-immunotherapy-response-in-gastricgej-cancer-100644388",false,"NCT07662005","Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric\u002FGEJ Cancer","Objective Sleep Characteristics and Response to Neoadjuvant Immunotherapy in Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma: A Prospective Observational Study","Inclusion Criteria:\n\n1. Age greater than 18 years, regardless of sex.\n2. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.\n3. Locally advanced, resectable disease as assessed by imaging or a multidisciplinary team, based on the 8th edition of the AJCC staging system, typically cT3-4a, any N, or any T with N-positive disease, corresponding to stage II-III disease, without distant metastasis.\n4. Scheduled to receive neoadjuvant therapy followed by radical surgery.\n5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.\n6. No prior systemic anticancer therapy for the current tumor at study baseline.\n7. Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis, peritoneal metastasis, or disease considered no longer suitable for curative-intent treatment.\n2. Prior neoadjuvant chemotherapy, immunotherapy, radiotherapy, or other systemic anticancer therapy for the current tumor.\n3. Severe cognitive impairment, acute psychiatric disorder, or any other condition that prevents the participant from completing study procedures.\n4. Current treatment with antidepressants, anxiolytics, sedative-hypnotics, or other psychotropic medications, with any of the following occurring within 4 weeks before enrollment:\n\n   1. Increase or decrease in the dose of the relevant medication by 25% or more from the previous maintenance dose;\n   2. Initiation, discontinuation, or replacement of antidepressants, anxiolytics, sedative-hypnotics, or other psychotropic medications;\n   3. Adjustment of treatment due to worsening anxiety, depression, insomnia, or other psychiatric or psychological symptoms;\n   4. Any medication change or psychological condition judged by the investigator to potentially affect sleep monitoring results or study compliance.\n5. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for this study.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective observational study will enroll 120 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who are scheduled to receive neoadjuvant immunotherapy followed by radical surgery. Non-invasive objective sleep monitoring will be performed during the neoadjuvant treatment period to assess sleep characteristics, including sleep duration, sleep efficiency, device-estimated deep sleep proportion, nocturnal awakenings, sleep regularity, heart rate, and heart rate variability. The primary objective is to evaluate the association between objective sleep characteristics and major pathological response (MPR) after neoadjuvant immunotherapy. This study will not alter standard treatment decisions, surgical procedures, or perioperative management.",[25,26,27,28],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Sleep","Pathological Response","NOT_YET_RECRUITING","2026-06-17",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":20},"2026-06-26",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"West China Second University Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100615182","circulating-micrornas-and-response-to-neoadjuvant-chemotherapy-in-breast-cancer-100615182","NCT07289282","Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer","The Relationship Between microRNAs in Breast Cancer Subtypes and Response to Neoadjuvant Chemotherapy and Pathological Response","miRNA-NAC","Inclusion Criteria:\n\n* Histologically confirmed breast cancer\n* Planned to receive neoadjuvant chemotherapy\n* Biologically female\n* Age ≥ 18 years\n* Ability to provide informed consent\n* Adequate organ function to receive standard NAC (based on routine clinical evaluation)\n\nExclusion Criteria:\n\n* Presence of metastatic disease at diagnosis\n* Prior systemic chemotherapy for breast cancer\n* Pregnancy or breastfeeding\n* Active infection or uncontrolled comorbid conditions interfering with study participation\n* Any condition preventing collection of blood samples","FEMALE",{"count":51,"type":20},80,"This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.",[54,55,28,56,57],"Breast Cancer","Neoadjuvant Therapy","Invasive Breast Carcinoma","MicroRNAs",[59,60,61,62,63],"microRNA","Circulating microRNAs","Neoadjuvant Chemotherapy","Pathological Complete Response","Predictive Biomarkers","RECRUITING","2026-03-30",{"date":67,"type":33},"2026-03-31",{"date":69,"type":33},"2025-12-15",{"date":71,"type":20},"2026-12",{"name":73,"class":40},"Atlas University",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":74},"100478631","phase-2-camrelizumab-plus-apatinib-and-temozolomide-as-neoadjuvant-in-high-risk-acral-melanoma-100478631","NCT05512481","Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma","Inclusion Criteria:\n\n1. age:18-75 years, male or female.\n2. Histopathologically confirmed acral melanoma (stage Ⅱ\u002FⅢ).\n3. Has not received any systematic anti-tumor drug treatment.\n4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.\n5. ECOG 0-1.\n6. Adequate organ function.\n7. Life expectancy of greater than 12 weeks.\n8. Patient has given written informed consent.\n\nExclusion Criteria:\n\n1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.\n2. Known history of hypersensitivity to any component of apatinib, temozolomide, Camrelizumab.\n3. Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);\n4. Subjects with any active autoimmune disease or history of autoimmune disease\n5. Patients with any unstable systemic disease, including but not limited to: serious infection, uncontrolled diabetes, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, myocardial infarction, congestive heart failure, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease;\n6. Received a live vaccine within 4 weeks of the first dose of study medication.\n7. Pregnancy or breast feeding.\n8. Decision of unsuitableness by principal investigator or physician-in charge.","75 Years",{"count":84,"type":20},60,"INTERVENTIONAL",[87],"PHASE2","Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.",[90,91,92,93,94,95,28],"Melanoma","Acral Melanoma","Temozolomide","Apatinib","Camrelizumab","Neoadjuvant",[91,97,98,99],"Immune Checkpoint Inhibitors","Protein Kinase Inhibitors","Antineoplastic Agents, Alkylating","2025-02-28",{"date":102,"type":33},"2025-03-03",{"date":104,"type":33},"2022-09-13",{"date":106,"type":20},"2026-12-31",{"name":108,"class":40},"Peking University Cancer Hospital & Institute"]